Marked improvement of platelet transfusion refractoriness after bortezomib therapy in multiple myeloma

International Journal of Hematology

Volumn 89, Issue 2, 2009, Pages 223-226

  Miki, Hirokazu ^a,b   Ozaki, Shuji ^a,b   Tanaka, Osamu ^a,b   Lee, Etsuko ^b   Takimoto, Tomomi ^b   Watanabe, Hirofumi ^b   Fujii, Shiro ^a,b   Nakamura, Shingen ^a,b   Kagawa, Kumiko ^a,b   Takeuchi, Kyoko ^a,b   Yata, Ken Ichiro ^a,b   Abe, Masahiro ^a,b   Kagami, Shoji ^b   Matsumoto, Toshio ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Anti HLA class I antibody; Bortezomib; Multiple myeloma; Platelet transfusion refractoriness

Indexed keywords

ALLOANTIBODY; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; HLA ANTIBODY; IMMUNOGLOBULIN G; MELPHALAN; PREDNISOLONE; THALIDOMIDE; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CASE REPORT; CHEMOTHERAPY; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HLA MATCHING; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LABORATORY TEST; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PANCYTOPENIA; PLASMA CELL; RECURRENT DISEASE; THROMBOCYTE TRANSFUSION;

ANTIBODIES; BORONIC ACIDS; DEXAMETHASONE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PLATELET TRANSFUSION; PYRAZINES; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS;

EID: 67349204419     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0255-z     Document Type: Article

References (10)

1. P Rebulla 2005 A mini-review on platelet refractoriness Haematologica 90 247 253
2. RA Kyle SV Rajkumar 2004 Multiple myeloma N Engl J Med 351 1860 1873 10.1056/NEJMra041875
3. S Ozaki O Tanaka S Fujii Y Shigekiyo H Miki M Choraku K Kagawa J Asano K Takeuchi K Kitazoe T Hashimoto M Abe T Matsumoto 2007 Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma Int J Hematol 86 180 185 10.1532/IJH97.07030
4. B Barlogie J Shaughnessy G Tricot J Jacobson M Zangari E Anaissie R Walker J Crowley 2004 Treatment of multiple myeloma Blood 103 20 32 10.1182/blood-2003-04-1045
5. S Jagannath BG Durie J Wolf E Camacho D Irwin J Lutzky 2005 Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma Br J Haematol 129 776 783 10.1111/j.1365-2141.2005. 05540.x
6. PG Richardson P Sonneveld MW Schuster D Irwin EA Stadtmauer T Facon 2005 Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2487 2498 10.1056/NEJMoa043445
7. A Nencioni F Grünebach F Patrone A Ballestrero P Brossart 2007 Proteasome inhibitors:antitumor effects and beyond Leukemia 21 30 36 10.1038/sj.leu.2404444
8. A Nencioni K Schwarzenberg KM Brauer SM Schmidt A Ballestrero F Grünebach P Brossart 2006 Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation Blood 108 551 558 10.1182/blood-2005-08- 3494
9. S Meister U Schubert K Neubert K Herrmann R Burger M Gramatzki S Hahn S Schreiber S Wilhelm M Herrmann HM Jäck RE Voll 2007 Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition Cancer Res 67 1783 1792 10.1158/0008-5472.CAN-06-2258
10. K Neubert S Meister K Moser F Weisel D Maseda K Amann 2008 The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis Nat Med 14 748 755 10.1038/nm1763